FOR IMMEDIATE RELEASE: September 8, 2017
Contact: Brad Bullen
(781) 647-3700 ext. 570
Nova Biomedical Launches New Veterinary Critical Care Analyzer
Stat Profile Prime Plus VET
New technologies improve testing, animal care, and profitability
Waltham, MA–Nova Biomedical is pleased to announce the domestic and international launch of Stat Profile Prime Plus VET, the latest addition to the Stat Profile line of veterinary critical care analyzers. Prime Plus VET is the most comprehensive veterinary critical care analyzer, offering 22 critical care tests including unique tests for BUN, creatinine, and ionized magnesium. Prime Plus VET also features maintenance-free sensor technology, non-lysing co-oximetry, automated quality control (QC), and species-specific references ranges to offer veterinary practices important clinical, financial, and workflow benefits.
Prime Plus VET delivers a comprehensive critical care panel in about one minute from 135 µL of whole blood. Tests include pH, PCO2, PO2, SO2%, Na, K, Cl, iCa, iMg, TCO2, glucose, lactate, urea, creatinine, Hct, Hb, O2Hb, COHb, MetHb, HHb, HbF, and tBil.
The analyzer incorporates Nova’s innovative, maintenance-free technology with individual MicroSensor cards, calibrator cartridges, and quality control cartridges. This design eliminates maintenance, improves analyzer uptime, and reduces testing costs—improving workflow and allowing staff to focus on animal care.
Prime Plus VET also provides a complete co-oximetry panel without chemically or mechanically lysing the blood. This eliminates corrosive lysing reagents and mechanical complexity, improving instrument reliability and reducing costs. A unique safety sample port allows for easy docking and hands-free sampling, and the Clot Block™ sample flow path protects sensors from blood clot blockages and related downtime.
Prime Plus VET features total quality monitoring with automated QC that verifies analyzer accuracy and precision on assayed liquid controls, and supplemental quality monitoring that electronically monitors and verifies correct performance for all analytical components for each analysis and calibration.
Prime Plus VET improves veterinary practice profitability through in-house diagnostics and optimizes billing with a simple bidirectional interface to practice management systems. The analyzer also features a powerful data management system, remote analyzer review and control of network-connected Prime Plus VET analyzers, and the most comprehensive cybersecurity features to protect information and prevent viruses.
“We at Nova Biomedical are extremely excited to launch the next addition to the veterinary Stat Profile Prime platform with Prime Plus VET,” said Brad Bullen, BS, RCP, sales product line manager at Nova. “Prime Plus VET introduces technology that expands critical care testing with unique assays and eliminates sensor and co-oximeter maintenance, all of which improves uptime and reduces costs. Prime Plus represents the latest in veterinary critical care testing technology and further demonstrates Nova’s leadership and history of innovation.”
About Nova Biomedical
Incorporated in 1976 and based in Waltham, MA, Nova Biomedical is a world leader in the development and manufacturing of state-of-the-art, whole blood, point-of-care and critical care analyzers, as well as providing the biotechnology industry with the most advanced instruments for cell culture monitoring. Nova is one of the fastest growing in vitro diagnostic companies in the world. Nova’s biosensor technology is incorporated in products ranging from handheld meters for glucose self- and point-of-care testing to critical care whole blood analyzers designed for rapid measurement of over 20 analytes. Nova’s biotechnology-specific BioProfile line has pioneered comprehensive cell culture testing, providing over 16 critical cell culture tests with 12 unique instrument offerings for broad range of cell culture applications. Nova employs over 1,200 people worldwide and has wholly owned subsidiaries located in Brazil, Canada, France, Germany, Great Britain, Italy, Japan, Spain, Switzerland, and Taiwan.